A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.
B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME). Their anti-tumor functions include recognizing tumor-associated antigens, ...
B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME). Their anti-tumor functions include recognizing tumor-associated antigens, ...
DESTIN, Fla. — An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according to a speaker at the Congress of Clinical Rheumatology East ...
The immune system is responsible for safeguarding the body from external and internal dangers. It does this, for the most part, by targeting and eliminating perceived threats ranging from invading ...
About five million people worldwide have systemic lupus erythematosus (SLE), an autoimmune disease that damages organs and tissues throughout the body, including skin, joints, kidneys, heart, and ...
Just returned from ASN 2025 Kidney Week in Houston, Dr Pietro A. Canetta reports that there was major excitement surrounding new drug developments for glomerular diseases, especially immunoglobulin A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results